Record to update:
Adverse Occurrence type:
MPHO Type:
Estimates Frequency:
Most recent risk assessment for medulloblastoma (Council of Europe, 2017): these WHO grade for tumors are considered to represent intermediate to high risk for transmission dependent upon different international recommendations which are being adjusted with increasing evidence. Childhood medulloblastomas are known to metastasize outside of the CNS and this risk may be increased in the setting of prior surgical intervention or chemo/radiotherapy.
Time to detection:
4 months
Alerting signals, symptoms, evidence of occurrence :
Three recipients from one donor: Kidney, kidney-pancreas and heart recipients developed disseminated tumors resulting in the death of two. The kidney-pancreas recipient had the pancreas graft removed 3 days after transplant due to arterial thrombosis. The patient developed anuria and renal allograft enlargement at 4 months, and died at 5 months due to tumoral infiltration of the kidney graft and lymph nodes. No response to reduced immunosuppression. The second kidney recipient had the graft removed due to the findings in the first recipient. This graft had tumoral infiltration and there were lymphatic metastases. The patient received chemotherapy and was alive and disease-free 12 months after the transplant. The heart recipient developed fever and asthenia with tumor involving liver and bone marrow and died at an unspecified time interval.
Demonstration of imputability or root cause:
Condition known in the donor whose cause of death was medulloblastoma after placement of a ventricular shunt, surgery, radiotherapy and chemotherapy. More than one recipient affected
Imputability grade:
3 Definite/Certain/Proven
Groups audience:
Suggest new keywords:
case report
deceased donor
kidney transplant
pancreas transplant
heart transplant
histological analysis
medulloblastoma (WHO grade 4)
chemotherapy
graft removal
metastasis
trnsplantectomy
CNS neoplasia
Adverse occurrence description:
Case Report: Medulloblastoma